

Appendix 4C Quarterly Cash Flow and Market Update

Australian Dairy Nutritionals Limited (**AHF** or the **Group**) today lodged its Appendix 4C and provided a review of the Group's progress for the quarter ended 31 December 2025 (**Q2 FY26**).

Quarterly Activity Report (QAR)

Financial Update

The Group is pleased to announce consolidated revenue of \$1.4m and of nutritional powders of \$776k for Q2 FY26. Nutritional powder sales represent a 152% increase on the pcp (Q2 FY25), with the result reflecting further pipeline and replenishment orders for increased distribution of the Future brand in China and contract pack sales to key customers. Nutritional powder sales in Q2 FY26 were negatively affected by sudden regulatory & registration changes in Vietnam, impacting packaging that resulted in stock returns. It is expected that shipments with revised packaging will begin at the end of Q3 FY26.

Total revenue in Q2 FY26 of \$1.4m is a 19% decrease on pcp (Q2 FY25) which was a direct result of stock returns in Vietnam and significantly lower milk and livestock sales v pcp, which was due to the exit from the lease of the North Brucknell farm. Total revenue for the H1 FY26 is 15% ahead of pcp (H1 FY25) and growth is expected to strongly accelerate in H2 FY26 due to the on-going distribution build of Future brand in China, and the resolution of the regulatory issue in Vietnam.

Net cash outflows from operations were in line with expectations at \$1.11m for Q2 FY26. The Group ended Q2 FY26 with cash holdings of \$809k (Q1 FY26: \$1.9m). It is also noted the Groups 2-year, \$1.22m funding facility expired in December and security over assets has been removed.

Directors, being related parties of the Group, were paid remuneration in the amount of \$80k during the December quarter, as outlined in item 6.1 of the attached Appendix 4C, which is consistent with the previous quarter.

Sales update

The business continues to invest in building distribution and consumer trial of the Future brand in the o2o channel in China via the M2C global shopping app. Distribution has been expanded to seven provinces in China and it is planned that further distribution and province penetration expansion will continue throughout H2 FY26, and is expected to reach 1,000 active stores by the end of FY26.

The release of this announcement was authorised by the Board of AHF.

For personal use only
Ends

Further Details

Australian Dairy Nutritionals Limited

Phone: +61 3 8692 7284

Email: shareholders@adnl.com.au

About Australian Dairy Nutritionals Group

Australian Dairy Nutritionals Group (AHF) is a vertically integrated Australian dairy group which owns high quality organic and organic A2 protein dairy farms, and a processing facility located in Southwestern Victoria, the 'Golden Triangle' of Australia's dairy industry. The Group produces the Ocean Road Dairies Organic A2 protein infant formula range, Australia's first Organic A2 protein infant formula made with farm fresh Australian milk from our organic dairy farms and manufactured at our infant formula factory in Camperdown, Victoria.

Disclaimer – Forward Looking Statements

This announcement may include "forward looking statements" within the meaning of securities laws of applicable jurisdictions. These forward-looking statements are not historical facts but are based on AHF's current expectation, estimates and projections about the industry, in which it operates, and beliefs and assumptions. Readers are cautioned not to place undue reliance on forward looking statements. All figures are unaudited.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Australian Dairy Nutritionals Limited

ABN

36 057 046 607

Quarter ended (“current quarter”)

31 December 2025

| Consolidated statement of cash flows | Current quarter \$A'000 | Year to date (6 months) \$A'000 |
|---|----------------------------|---------------------------------------|
| 1. Cash flows from operating activities | | |
| 1.1 Receipts from customers | 1,603 | 3,835 |
| 1.2 Payments for | | |
| (a) research and development | - | - |
| (b) product manufacturing and operating costs | (1,675) | (3,594) |
| (c) advertising and marketing | (124) | (217) |
| (d) leased assets | - | - |
| (e) staff costs | (479) | (941) |
| (f) administration and corporate costs | (432) | (855) |
| 1.3 Dividends received (see note 3) | - | - |
| 1.4 Interest received | 4 | 14 |
| 1.5 Interest and other costs of finance paid | (11) | (11) |
| 1.6 Income taxes paid | - | - |
| 1.7 Government grants and tax incentives | - | - |
| 1.8 Other (provide details if material) | - | - |
| 1.9 Net cash from / (used in) operating activities | (1,114) | (1,769) |
| 2. Cash flows from investing activities | | |
| 2.1 Payments to acquire or for: | | |
| (a) entities | - | - |
| (b) businesses | - | - |
| (c) property, plant and equipment | (159) | (263) |
| (d) investments | - | - |
| (e) intellectual property | - | - |
| (f) other non-current assets | - | - |

| Consolidated statement of cash flows | Current quarter \$A'000 | Year to date (6 months) \$A'000 |
|---|------------------------------------|--|
| 2.2 Proceeds from disposal of: | | |
| (a) entities | - | - |
| (b) businesses | - | - |
| (c) property, plant and equipment | - | - |
| (d) investments | - | - |
| (e) intellectual property | - | - |
| (f) other non-current assets | - | - |
| 2.3 Cash flows from loans to other entities | - | - |
| 2.4 Dividends received (see note 3) | - | - |
| 2.5 Other (provide details if material) | - | - |
| 2.6 Net cash from / (used in) investing activities | (159) | (263) |
| 3. Cash flows from financing activities | | |
| 3.1 Proceeds from issues of equity securities (excluding convertible debt securities) | - | - |
| 3.2 Proceeds from issue of convertible debt securities | - | - |
| 3.3 Proceeds from exercise of options | - | - |
| 3.4 Transaction costs related to issues of equity securities or convertible debt securities | - | - |
| 3.5 Proceeds from borrowings | 327 | 327 |
| 3.6 Repayment of borrowings | (127) | (127) |
| 3.7 Transaction costs related to loans and borrowings | - | - |
| 3.8 Dividends paid | - | - |
| 3.9 Other – lease liabilities | (13) | (47) |
| 3.10 Net cash from / (used in) financing activities | 187 | 153 |
| 4. Net increase / (decrease) in cash and cash equivalents for the period | | |
| 4.1 Cash and cash equivalents at beginning of period | 1,895 | 2,688 |
| 4.2 Net cash from / (used in) operating activities (item 1.9 above) | (1,114) | (1,769) |
| 4.3 Net cash from / (used in) investing activities (item 2.6 above) | (159) | (263) |

| Consolidated statement of cash flows | | Current quarter \$A'000 | Year to date (6 months) \$A'000 |
|--|---|------------------------------------|--|
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | 187 | 153 |
| 4.5 | Effect of movement in exchange rates on cash held | - | - |
| 4.6 | Cash and cash equivalents at end of period | 809 | 809 |
| 5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | | Current quarter \$A'000 | Previous quarter \$A'000 |
| 5.1 | Bank balances | 809 | 1,395 |
| 5.2 | Term deposits | - | 500 |
| 5.3 | Bank overdrafts | - | - |
| 5.4 | Other (provide details) | - | - |
| 5.5 | Cash and cash equivalents at end of quarter (should equal item 4.6 above) | 809 | 1,895 |
| 6. Payments to related parties of the entity and their associates | | Current quarter \$A'000 | |
| 6.1 | Aggregate amount of payments to related parties and their associates included in item 1 | | 80 |
| 6.2 | Aggregate amount of payments to related parties and their associates included in item 2 | | - |
| <i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i> | | | |

| 7. Financing facilities | | Total facility amount at quarter end \$A'000 | Amount drawn at quarter end \$A'000 |
|--|---|--|--|
| | <i>Note: the term 'facility' includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i> | | |
| 7.1 | Loan facilities | - | - |
| 7.2 | Credit standby arrangements | - | - |
| 7.3 | Other (please specify) | 200 | 200 |
| 7.4 | Total financing facilities | 200 | 200 |
| 7.5 | Unused financing facilities available at quarter end | | - |
| 7.6 | Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. | 7.3 Hunter Premium Funding (Insurance) – Unsecured short-term loan facility. Flat interest rate: 5.25% | |
| 8. Estimated cash available for future operating activities | | \$A'000 | |
| 8.1 | Net cash from / (used in) operating activities (item 1.9) | | (1,114) |
| 8.2 | Cash and cash equivalents at quarter end (item 4.6) | | 809 |
| 8.3 | Unused finance facilities available at quarter end (item 7.5) | | 0 |
| 8.4 | Total available funding (item 8.2 + item 8.3) | | 809 |
| 8.5 | Estimated quarters of funding available (item 8.4 divided by item 8.1) | | 0.73 |
| | <i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i> | | |
| 8.6 | If item 8.5 is less than 2 quarters, please provide answers to the following questions: | | |
| 8.6.1 | Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? | Answer: The Group expects to increase cash flows in the medium term as it continues to increase distribution and sales of its branded infant formula ranges. | |
| 8.6.2 | Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? | Answer: The Board has and continues to assess capital raising opportunities and remains confident that it will be able to raise sufficient capital as and when required to fund its future operations. | |
| 8.6.3 | Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? | Answer: Yes, as set out in section 8.6.2. | |
| | <i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i> | | |

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 21 January 2026

Authorised by: the Board of Directors
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.